- Home
- MDAI vs FGEN Comparison
MDAI vs FGEN Comparison
Compare MDAI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- FGEN
- Stock Information
- Founded
- MDAI 2013
- FGEN 1993
- Country
- MDAI United States
- FGEN United States
- Employees
- MDAI 78
- FGEN N/A
- Industry
- MDAI Medical/Dental Instruments
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- FGEN Health Care
- Exchange
- MDAI Nasdaq
- FGEN Nasdaq
- Market Cap
- MDAI 33.1M
- FGEN 33.5M
- IPO Year
- MDAI N/A
- FGEN 2014
- Fundamental
- Price
- MDAI $1.22
- FGEN $0.31
- Analyst Decision
- MDAI Strong Buy
- FGEN Strong Buy
- Analyst Count
- MDAI 2
- FGEN 1
- Target Price
- MDAI $4.75
- FGEN $10.00
- AVG Volume (30 Days)
- MDAI 149.5K
- FGEN 521.4K
- Earning Date
- MDAI 05-13-2025
- FGEN 05-12-2025
- Dividend Yield
- MDAI N/A
- FGEN N/A
- EPS Growth
- MDAI N/A
- FGEN N/A
- EPS
- MDAI N/A
- FGEN N/A
- Revenue
- MDAI $29,581,000.00
- FGEN $29,621,000.00
- Revenue This Year
- MDAI N/A
- FGEN $232.81
- Revenue Next Year
- MDAI $102.58
- FGEN $9.16
- P/E Ratio
- MDAI N/A
- FGEN N/A
- Revenue Growth
- MDAI 63.83
- FGEN N/A
- 52 Week Low
- MDAI $0.82
- FGEN $0.18
- 52 Week High
- MDAI $3.25
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- MDAI 40.42
- FGEN 50.93
- Support Level
- MDAI $1.25
- FGEN $0.28
- Resistance Level
- MDAI $1.32
- FGEN $0.34
- Average True Range (ATR)
- MDAI 0.05
- FGEN 0.02
- MACD
- MDAI 0.00
- FGEN 0.00
- Stochastic Oscillator
- MDAI 28.57
- FGEN 60.28
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.